Clinical Trial Update: Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating transdermal oxybutynin for overactive bladder with a neurological condition has completed and results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Detrusor Hyperreflexia
• Overactive Bladder

Drugs mentioned

• Transdermal oxybutynin (oxybutynin)

Snippet

Sponsor: Watson Pharmaceuticals | Conditions: Detrusor Hyperreflexia | Phase 4 | Status: COMPLETED | Results posted: 2009-12-23